Press Release


					
ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors

					

					


					

						

							

								
Barcelona, Spain, 23 May 2023: ONA Therapeutics (“ONA”), which is specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer, is pleased to announce the appointment of Dr. Pamela Klein as independent member to its board of directors.


Dr. Pamela Klein is a medical oncologist and seasoned biotechnology executive with 20 years of experience in drug development. Amongst multiple roles and experience, she is a member of the Board of Directors of Argenx, Patrys and I-Mab Biopharma as well as a member of several Scientific Advisory Boards. Dr. Klein was previously Chief Medical Officer of Olema Oncology and previously served in that role for multiple successful biotech companies including Intellikine which was acquired by Takeda. From 2001-2008, Dr. Klein held increasing positions of responsibility at Genentech lastly as Vice President, Development, where she led the development for a portfolio of drugs including Herceptin®, Rituxan®, Perjeta®, and Tarceva®. Prior to this, Dr. Klein was Research Director for the National Cancer Institute-Navy Breast Care Center that she co-founded and led until leaving the NCI.


Dr. Klein received her bachelor’s degree in biology from California State University and her Medical Degree from Stritch School of Medicine, Loyola University Chicago. She trained in internal medicine at Cedars-Sinai Medical Center in Los Angeles and medical oncology at the National Cancer Institute in Bethesda, Maryland where she served as Chief Fellow.


Valerie Vanhooren, Ph.D., Co-founder & Chief Executive Officer of ONA Therapeutics, said: “I am delighted to welcome Pamela to the board at a pivotal time of Company growth with her proven track record in developing therapies that have raised the bar in patient care. Pamela’s insight and unparalleled experience in the field of oncology will be invaluable as we advance our treatments for advanced cancer towards clinical development.”


Dr Pamela Klein, Member of the Board of Directors at ONA Therapeutics, commented: “I look forward to working with the team at ONA Therapeutics, whose novel approach has the potential to make a real difference and improve patient outcomes with advanced cancer.”


ONA Therapeutics is developing novel therapies against advanced cancer and will be profiled in Nature on the 25 of May as a thriving, preclinical, mature Company which is accelerating development of its novel pipeline towards clinical development.


							

						

					

				

			

		

	

			

					


					
			
  
  
  
  














    
  
  
  
    

          
        
            

        


  Ona Therapeutics


        
    
          

  • 
  

    • 

  
  • 
    
  
    • 


  
  • 
    
  
    • 


  
  • 
    
  
    • 
        

        


  		Powered by ONA THERAPEUTICS, SL  GDPR Cookie Compliance
		

      

      
      

        

           
        

        
        


          

            


      Privacy Overview
    

  	
ONA THERAPEUTICS, SL obtains personal data through the contact forms of the web, from those who submit any questions, requests and / or comments.


In accordance with current regulations on Data Protection, specifically, Regulation (EU) 2016/679 of the European Parliament and of the Council, of April 27, 2016, personal data provided to ONA THERAPEUTICS, SL through this web portal will become part of its information systems that comply with the security measures required in order to guarantee the confidentiality, integrity, security and information retrieval.


The purposes for which these data are collected are those of being able to respond to your queries regarding the services we offer. In addition, of the timely response to your queries, we may, if you authorize us to do so, send you information electronically.


Your data will be kept for the period that you are registered to receive the requested information, being your revocable consent, it may be withdrawn at any time through the link that accompanies each shipment to communicate your WITHDRAWN or through an email to the address info@ona-therapeutics.com. From that moment, you will no longer receive any communication from us.


We will not proceed with the communication or transfer of your data, in any case, unless a public body requires it in accordance with the Law and those in charge of treatment that provide services related to our information systems.


You have the right to obtain confirmation about whether we are treating your personal data, therefore, you have the right to access your personal data (Right of Access), you have the right to rectify inaccurate data (Right of Rectification) or to request its deletion (Right to deletion) when the data is no longer necessary, you have the right to exercise your opposition to the processing of data (Right of opposition), to exercise your right to the limitation of the processing, as well as you will have the right to the portability of your data, if it is the case. All this by writing to our access addresses in Calle Baldiri Reixach 10, Barcelona, ​​Spain or via email info@ona-therapeutics.com in accordance with the procedure of articles 15 to 23 of Regulation (EU) 2016 / 679 of the European Parliament and of the Council, of April 27, 2016.


ONA THERAPEUTICS, SL, declares to have implemented the necessary technical and organizational security measures that guarantee the security of the data and prevent its alteration, loss, treatment or unauthorized access, taking into account the state of the technology, the nature of the stored data and the risks to which they are exposed, already come from human action or from the physical or natural environment.


To protect the privacy of the USERS, it is prohibited to send any information regarding their ideology, religion, beliefs, racial origin, health, and sexual life through our forms.


Likewise, we inform you that, under no circumstances will automated individual decisions or profiling be made.